Table of Contents Table of Contents
Previous Page  593 / 1082 Next Page
Information
Show Menu
Previous Page 593 / 1082 Next Page
Page Background

S577

ESTRO 36 2017

_______________________________________________________________________________________________

Purpose or Objective

Postoperative concurrent chemoradiotherapy (CCRT) is

supprior to RT alone for squamous cell carcinoma of the

head and neck (SCCHN) with high-risk factors (such as

extracapsular invasion, positive resection margin) by both

RTOG 9501 and EORTC 22931 trials. We developed a new

protocol of intensive chemotherapy followed by IMRT

(IntCT+RT) and compared the toxicity and efficacy with

CCRT for patients with SCCHN and poor prognostic factors

after surgery.

Material and Methods

Ninety-two SCCHN patients who received curative

resection first and with at least one of the following

characteristics, resection margin involvement or close to

the tumor, extracapsular invasion, perineural invasion,

angiolymphatic invasion, pathological stage T4, and

multiple neck nodes metastasis were eligible for this

study.

Postoperative

multi-drugs

combination

chemotherapy (Methotrexate 30 mg/m2 d1, Epirubicin 30

mg/m2 d1, alternating with Mitomycin-C 4 mg/m2 d8,

Oncovin 1 mg/m2 d8, Cisplatin 25 mg/m2 d8, Leucovorin

120 mg/m2 d8, 5-fluoroUracil 1000 mg/m2 d8, and

Bleomycin 10 mg/m2 d8) for 10-12 weeks were

administered followed by IMRT in the IntCT+RT groups.

Patient in the CCRT group received similar RT and

concurrent chemotherapy of either tri-weekly cisplatin

100mg/m2 alone or tri-weekly cisplatin 50mg/m2 plus oral

tegafur-uracil 2# bid for 7 weeks.

Results

The IntCT+RT group (n=37) had less regional (8.1% vs.

12.7%) and distant (2.7% vs. 7.3%) failures, compared with

the CCRT group (n=55). The Kaplan-Meier survival analyses

revealed that patients treated by IntCT+RT had better

regional failure-free survival (3-year rate, 94.5% vs. 72.4%,

P=0.0294) and overall survival (75.9% vs. 61.8%, P=0.1343)

than those who received CCRT. Grade 3/4 acute toxicity

of IntCT phase included leucopenia (51.4%), anemia

(27.0%), vomiting (5.4%), alopecia (5.4%) and mucositis

(2.7%) but patients could tolerate it well. During RT

period, patients in the CCRT group had significantly higher

grade 3/4 mucositis (76.4% vs. 57.7%, P=0.0356) and

vomiting (27.3% vs. 0%, P<0.0001) than those in the IntCT-

RT group.

Conclusion

IntCT+RT in postoperative setting for high-risk SCCHN

patients is feasible. We observe a significant better

regional control, favorable overall survival and less grade

3 or 4 mucositis and vomiting in the IntCT-RT group

compard with the CCRT. This novel approach deserves to

be studied in a phase III randomized trial.

EP-1056 Radiation and concurrent superselective

intra-arterial cisplatin for maxillary sinus cancer

T. Ebara

1

, K. Ando

1

, M. Kawahara

1

, M. Suzuki

2

, H.

Horikoshi

3

, Y. Tamaki

4

1

Gunma Prefectural Cancer Center, Division of Radiation

Oncology, Ota, Japan

2

Gunma Prefectural Cancer Center, Division of Head and

Neck Surgery, Ota, Japan

3

Gunma Prefectural Cancer Center, Division of

Radiology, Ota, Japan

4

Tsukuba University Hospital, Department of Radiation

Oncology, Tsukuba, Japan

Purpose or Objective

This study aimed to evaluate the efficacy of radiation and

concomitant superselective high-dose intra-arterial

cisplatin (RADPLAT) for maxillary sinus squamous

carcinoma (MS-SCC).

Material and Methods

We conducted a retrospective chart review of MS-SCC

patients treated with RADPLAT between 2008 and June

2016.

Results

Thirty-four MS-SCC patients were received RADPLAT.

There were 9 patients (26%) diagnosed with T3, 14 (41%)

with T4a, and 11 (32%) with T4b disease. Lymph-node

involvement was present in 6 patients. Cisplatin with

median 150 mg was administered using the superselective

intra-arterial infusion method bi-weekly. Of them, 29, 3,

1 and 1 patients were received 4, 3, 2 and 1 times cisplatin

infusions, respectively. Radiation, ranged with 50–74 Gy

with median 60 Gy was administered by 2 Gy fraction in 5

times a week. The median follow-up was 24.6 months,

ranged with 4.1-92.4 months. Complete responses in the

primary site were obtained in 11 (32%) patients and partial

responses in 19 (56%) patients. The 2 and 5-year overall

survival rates (OS) were 66 and 45%, respectively. The 2

and 5-year primary-site recurrence free survival rates

(PRFS) were 49 and 40%, respectively. The 2 and 5-year

disease-free survival rates (DFS) were 45 and 37%,

respectively. The patients with T3 showed significantly

better OS (p=0.03). The patients with 4 time infusions

showed significantly better OS, PRFS, and DFS (p<0.05).

There was no life-threatening toxicity.

Conclusion

In RADPLAT for MS-SCC, 4 times cisplatin infusions could

improve the

prognosis.

EP-1057 Predictive and prognostic value of

pretreatment [18F] FDG-PET parameters in head-and-

neck cancer

L. Deantonio

1

, M. Paolini

1

, E. Puta

2

, L. Vigna

3

, R.

Matheoud

3

, L. Masini

1

, G. Sacchetti

2

, M. Brambilla

3

, M.

Krengli

1

1

University Hospital Maggiore della Carità,

Radiotherapy, Novara, Italy

2

University Hospital Maggiore della Carità, Nuclear

Medicine, Novara, Italy

3

University Hospital Maggiore della Carità, Medical

Physics, Novara, Italy

Purpose or Objective

To evaluate the predictive and prognostic value of [F18]

FDG-PET parameters performed prior to radiotherapy in

head-and-neck cancer patients.

Material and Methods

Thirty-eight patients with newly diagnosed head-and-neck

cancer treated with concomitant chemoradiotherapy

underwent [F18] FDG-PET before the treatment course.

The maximum and the mean standardized uptake value

(SUVmax, SUVmean), the metabolic tumor volume (MTV),

and total lesion glycolysis (TLG) were analysed. Multiple

threshold levels were tested in order to define the most

suitable threshold value for the metabolic activity of each

patient's tumour: the fixed threshold of the 41% and 50%

of the maximum uptake value (SUV41%, SUV50%) and an

adaptive threshold algorithm (ATA) implemented on the

iTaRT workstation (Tecnologie Avanzate, Italy). We

evaluated the relationship of mean values of SUVmax,

SUVmean, MTV, and TLG with tumour characteristics,

treatment response, local recurrence, distant metastasis

and

disease-related

death.

Receiver-operating

characteristic (ROC) curve analysis was done to obtain

optimal predictive cut-off values for PET parameters.

Disease-free (DFS) and overall survival (OS) disease-

related were examined according to these cut-offs.

Results

The mean value and range of each parameters were

calculated (Table1).

Higher SUVmean

ATA

was associated to higher primary

tumour staging (p= 0.04).

Thirty-two/38 patients (84.2%) had a complete response,

4/38 (10.5%) a partial response, and 2/38 (5.2%) a no

response 8 weeks after the completion of treatment. SUV

parameters resulted not predictive of tumour response.

After a median follow-up of 22 months, 6/38 (15.8%)

patients developed local recurrence and 6/38 (15.8%)